What the FDA Approval of Nemolizumab Means for Prurigo Nodularis, with Gil Yosipovitch, MD 

On August 13, the FDA approval of nemolizumab (Nemluvio) for adults with prurigo nodularis was announced. Prurigo nodularis is a chronic neuroimmune skin disease affecting around 181,000 individuals in the US and is a condition characterized by intense itch.
The approval of this drug follows positive phase 3 findings from the OLYMPIA clinical trials. One of the investigators-Gil Yosipovitch, MD, professor of dermatology for the Miller School of Medicine at the University of Miami-spoke with HCPLive about the approval’s significance.
View the interview here: www.hcplive.co...
#PrurigoNodularis #FDA